Press Releases

Samsung Biologics Reports Strong Second Quarter 2021 Financial Results

Mateo Iglesias Vice President Marketing & Sales Sakura Finetek Europe

Sakura Finetek Europe has announced the appointment of Mr. Mateo Iglesias as Vice President of Marketing & Sales EMEAI.

CluePoints partners with ZS to provide best-in-class RBQM expertise and technology, increasing clinical trial efficiency and improving patient outcomes

CluePoints, the premier provider of risk-based quality management (RBQM) and data oversight software for clinical trials, has partnered with ZS, a global professional services firm with technology and analytics expertise in biopharma, to offer innovative capabilities in portfolio-level performance oversight.  The new partnership pairs a best-in-breed solutions company focused on study-level risk-based management with a pharmaceutical and biotech solutions provider with advanced capabilities in portfolio-level quality and operational oversight.

DFE Pharma Proudly Supports COVID-19 Vaccination Supply in Pakistan

BOC Sciences Offers Pseudouridine and Its Derivatives for RNA Improvement

Noxopharm Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active ingredient in Veyonda®, as an anti-inflammatory drug for early-stage COVID-19 treatments.

Certara’s Simcyp™ COVID-19 Vaccine Model Named Finalist in Both the 2021 Citeline Awards and R&D 100 Awards

Certara’s Simcyp COVID-19 Vaccine Model uses biosimulation to improve decision-making and help optimize dosing regimens of COVID-19 vaccines. Certara calibrated its model using the structure of actual COVID-19 vaccines and validated it by replicating the published clinical data. The model, which is incorporated in Certara’s Vaccine Simulator™, addresses important questions such as differences in response with age and ethnicity, optimal timing between doses and expected duration of antibody response.

Histobiolab Involves Extensive Expertise in Providing Tissue Microarray to Satisfy Research Needs

Verana Health Partners with Komodo Health to Give Clinical Researchers Deeper Insight into Real-World Patient Journeys

Pairing Verana Health’s de-identified, outpatient EHR data with robust patient journey insight in Komodo’s Healthcare Map will arm life sciences researchers with complete view of patient encounters with the healthcare system

Microbiosci Develops Competent Services to Support B. licheniformis Genome Editing

Rho Granted Extension by National Institute of Allergy and Infectious Diseases to Study Rate of COVID-19 Infection in US Children Through April 2022

Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, today announced its Human Epidemiology and Response to SARS-CoV-2 (HEROS) study, to help determine the rate of the new coronavirus infection in children and their family members in the U.S. has been extended through April 2022. During the first year of the study, over 1,900 households containing close to 6,000 study participants were enrolled. The study is being conducted to determine what percentage of children infected with SARS-CoV-2, the virus that causes COVID-19, develop symptoms of the disease, as well as whether rates of SARS-CoV-2 infection differ between children who have asthma or other allergic conditions and children who do not. HEROS is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Matexcel Offers Metallurgy Service for Research Use

Inspirata Partners with King’s Health Partners ECMC and Guy’s and St Thomas’ NHS Foundation Trust to Evaluate the Application of AI Automation in Matching Patients with Cancer to Early Phase Clinical Trials

Inspirata has announced that King’s Health Partners ECMC and Guy’s and St Thomas’ NHS Foundation Trust will pilot its Trial Navigator™ software as part of an evaluation the organisations are conducting into how artificial intelligence based automation can improve the identification and efficiency of matching patients with cancer to early phase clinical trials.

Biotium Launches First Ever Mounting Media with Far-Red Nuclear Counterstain and Autofluorescence Quenching Reagent

Biotium has announced that it is significantly expanding its line of antifade wet-set and hardset EverBrite™ Mounting Medium by launching a new far-red nuclear counterstain, NucSpot® 640 — specific for the Cy®5 channel.

Cerba Research Awarded NIH Contract for Central Lab Services

Cerba Research today announced it was awarded a five-year contract for Clinical Central Laboratory Services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).

Profacgen Provides Tandem Affinity Purification Service for Protein Interaction Research

Biofourmis Earns FDA’s First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart Failure

Biofourmis completed a proof of concept study for its heart failure digital therapeutic BiovitalsHF that met its endpoint of number of patients at 50% of optimal therapy. As a result, FDA has granted the DTx the first-ever Breakthrough Designation for a heart failure digital therapy.

Sensyne grows medical research dataset to 60 million patients

Deep longitudinal, disease agnostic structured global dataset, covering over 4,000 indications will industrialize Sensyne’s life sciences activities

Glyscend Therapeutics Announces Preclinical Data at ADA 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Glyscend Inc has presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, from a study of its proprietary oral polymer duodenal exclusion therapy.

Speranza Therapeutics Announces Value-Based Program for Opioid Detox Facilities Program vows to reduce costly facility Against Medical Advice (AMA) Leave rates

Speranza Therapeutics has announced the launch of a value-based program for treatment facilities to reduce patient Against Medical Advice (AMA) rates utilizing the S.T. Genesis device.